Pliant Therapeutics, Inc.
Clinical trials sponsored by Pliant Therapeutics, Inc., explained in plain language.
-
New drug aimed at slowing liver damage in rare bile duct disease
Disease control CompletedThis Phase 2a trial tested an experimental oral drug called PLN-74809 in 121 adults with primary sclerosing cholangitis (PSC) and suspected liver fibrosis. The main goals were to check the drug's safety and how it moves through the body. Participants received either the drug or a…
Phase: PHASE2 • Sponsor: Pliant Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug shows promise in reducing lung scarring in small trial
Disease control CompletedThis phase 2a trial tested a drug called PLN-74809 in 10 people with idiopathic pulmonary fibrosis (IPF), a disease that causes progressive lung scarring. Participants took the drug or a placebo daily for 12 weeks. The study used a special PET/MRI scan to measure collagen (scar t…
Phase: PHASE2 • Sponsor: Pliant Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC